Kennedy Capital Management LLC Increases Stock Position in Evolent Health, Inc. (NYSE:EVH)

Kennedy Capital Management LLC grew its position in Evolent Health, Inc. (NYSE:EVH - Free Report) by 40.8% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 365,186 shares of the technology company's stock after buying an additional 105,748 shares during the period. Kennedy Capital Management LLC owned 0.31% of Evolent Health worth $4,108,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in EVH. Pilgrim Partners Asia Pte Ltd purchased a new position in Evolent Health in the fourth quarter worth approximately $26,000. R Squared Ltd purchased a new position in shares of Evolent Health during the 4th quarter worth $31,000. AlphaQuest LLC increased its position in shares of Evolent Health by 21,650.0% during the 4th quarter. AlphaQuest LLC now owns 3,045 shares of the technology company's stock worth $34,000 after purchasing an additional 3,031 shares during the last quarter. Parkside Financial Bank & Trust raised its holdings in Evolent Health by 90.7% in the 4th quarter. Parkside Financial Bank & Trust now owns 4,957 shares of the technology company's stock valued at $56,000 after buying an additional 2,358 shares during the period. Finally, AlphaCentric Advisors LLC purchased a new stake in Evolent Health in the 4th quarter valued at about $61,000.

Evolent Health Stock Performance

Shares of NYSE:EVH traded down $0.28 during midday trading on Friday, hitting $8.95. The stock had a trading volume of 2,978,007 shares, compared to its average volume of 2,317,381. Evolent Health, Inc. has a 1 year low of $8.35 and a 1 year high of $33.63. The company has a current ratio of 1.04, a quick ratio of 1.04 and a debt-to-equity ratio of 0.58. The stock has a 50 day moving average price of $9.66 and a two-hundred day moving average price of $13.41. The company has a market capitalization of $1.04 billion, a PE ratio of -10.92 and a beta of 1.20.

Evolent Health (NYSE:EVH - Get Free Report) last announced its quarterly earnings data on Thursday, February 20th. The technology company reported $0.03 earnings per share for the quarter, missing analysts' consensus estimates of $0.38 by ($0.35). Evolent Health had a positive return on equity of 5.73% and a negative net margin of 2.41%. The business had revenue of $646.54 million for the quarter, compared to analyst estimates of $650.92 million. As a group, equities analysts predict that Evolent Health, Inc. will post 0.08 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research firms have recently issued reports on EVH. Oppenheimer reduced their price target on shares of Evolent Health from $28.00 to $18.00 and set an "outperform" rating on the stock in a research note on Friday, January 24th. JMP Securities restated a "market outperform" rating and set a $12.00 price target on shares of Evolent Health in a research note on Friday, February 14th. Truist Financial decreased their target price on Evolent Health from $15.00 to $14.00 and set a "buy" rating on the stock in a research note on Thursday, April 10th. Stephens cut their price target on shares of Evolent Health from $16.00 to $12.00 and set an "equal weight" rating on the stock in a research note on Tuesday, January 21st. Finally, Needham & Company LLC restated a "buy" rating and issued a $15.00 price objective on shares of Evolent Health in a report on Friday, February 21st. One analyst has rated the stock with a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average target price of $17.64.

Insider Buying and Selling at Evolent Health

In other Evolent Health news, Director Brendan B. Springstubb bought 5,000 shares of the business's stock in a transaction on Tuesday, March 4th. The stock was bought at an average price of $8.75 per share, for a total transaction of $43,750.00. Following the completion of the transaction, the director now owns 11,842 shares in the company, valued at approximately $103,617.50. The trade was a 73.08 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, President Daniel Joseph Mccarthy purchased 11,040 shares of the stock in a transaction dated Thursday, March 6th. The stock was acquired at an average price of $9.01 per share, for a total transaction of $99,470.40. Following the completion of the transaction, the president now directly owns 389,004 shares of the company's stock, valued at approximately $3,504,926.04. The trade was a 2.92 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last three months, insiders purchased 74,000 shares of company stock valued at $666,315. Corporate insiders own 1.60% of the company's stock.

About Evolent Health

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.